Ann Baker and John Cole are speaking on this topic. This webinar will examine the motivations for collaboration between biopharma and academia – two different worlds. Crucially, we will also reflect on why the outcomes of such collaborations often disappoint and consider some of the interventions that both parties can make to ensure a successful outcome. We will look at how to bridge the gap between academia and biopharma.
For more information on this event, click here.
Disparities in screening and diagnosis for triple negative breast cancer
Gilead Sciences asked Charles River Associates and Tigerlily Foundation to examine the extent to which policies associated with triple negative breast cancer...